Close Menu
Invest Insider News
    Facebook X (Twitter) Instagram
    Monday, November 16
    Facebook X (Twitter) Instagram Pinterest Vimeo
    Invest Insider News
    • Home
    • Bitcoin
    • Commodities
    • Finance
    • Investing
    • Property
    • Stock Market
    • Utilities
    Invest Insider News
    Home»Stock Market»Cipla share price: HSBC expects 13% upside for the stock post Q1 results on firm US prospects.
    Stock Market

    Cipla share price: HSBC expects 13% upside for the stock post Q1 results on firm US prospects.

    July 29, 20243 Mins Read


    Stock Market today: Cipla share price that has gained more than 24% year to date is trading near 52 week highs it scaled on Friday. Cipla had reported strong Q1 performance with net profit rising 17% YoY largely helped by improved operating performance as reported Ebitda grew 14% though revenue grew t a slower pace of 7% year-on-year.

    While India Business contributing more than 40% to overall grew 5%, The strong US sales growth lifted the show.

    Get Quick Cash in Minutes!

    Best Personal Loan at Lowest Interest Rates

    Instant Apply

    Robust US performance- Cipla’s US sales at $250 million contributing 31.2% to the first quarter revenue) grew 12.6% y-o-y and10.6% sequentially. The same was helped by market share gains for key launches like hormone drug lanreotide, respiratory inhaler albuterol generics as well as well supported by higher generic Revlimid sales .

    Cipla further has indicates that it should sustain US sales of $235-240 mullion in remaining quarters of FY25, which remains a key positive

    Analysts at HSBC Securities and Capital Markets (India) Pvt Ltd believe lanreotide generic has plenty of room to grow as the brand still holds 78% share of the overall lanreotide market. Further there are three more peptides launches planned by Cipla over the next 12 months starting in 2HFY25. HSBC analysts say that the traction in existing products and peptide launches should help Cipla to sustain US sales growth in FY25 and beyond. This should also ease concerns regarding delays in the launch of respiratory products, as generics of Abraxane and generic Advair which remain delayed due to pending plant clearances by USFDA.

    For the domestic business growth , Cipla has highlighted that India Branded Prescription Business grew at a healthy rate of 10% yoy. it was the softness in Trade Generics Business owing to distribution model change that led to softer overall growth for Cipla Business.



    HSBC continues to like Cipla’s healthy outlook in key segments (India, South Africa, the US), delivery on cost efficiencies, and prudent capital allocation. Notable HSBC says that the pipeline products – inhalers and peptides should provide comfort for the growth outlook of US sales despite a high base. Their target price for Cipla revised upwards to ₹1,775 (from ₹1,680) indicates more than 13% uspide for Cipla share price.



    Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before taking any investment decisions




    Topics You May Be Interested In



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleJohnvents Industries DMCC Expands Global Reach with Launch of Uganda Operations, Targets Strategic Markets for Growth
    Next Article Bitcoin at Point of Cycle Right Before Parabolic Expansion, According to Crypto Analyst

    Related Posts

    Stock Market

    The Stock Market Is Doing Something for Only the 6th Time in 156 Years, and History Says It’s Clear What Comes Next for Stocks

    November 15, 2026
    Stock Market

    Dow Jones vs S&P 500: Key Differences Explained

    November 14, 2026
    Stock Market

    Stock Market Today, Nov. 13: Nvidia Slides After HSBC Downgrades Stock to Hold on CEO Uncertainty

    November 13, 2026
    Leave A Reply Cancel Reply

    Top Posts

    How is the UK Commercial Property Market Performing?

    December 31, 2000

    How much are they in different states across the US?

    December 31, 2000

    A Guide To Becoming A Property Developer

    December 31, 2000
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews
    Bitcoin

    Bitcoin High Stakes This March

    March 2, 2026
    Stock Market

    Dow sinks 1,000 points, S&P 500, Nasdaq tank with Trump’s tariffs, Powell bashing in focus

    April 21, 2025
    Investing

    MarineMax stock surges after Donerail’s $1 billion buyout offer By Investing.com

    February 2, 2026
    What's Hot

    Bitcoin Could Skyrocket by up to 365% This Cycle, According to Crypto Trader – But There’s a Catch

    July 18, 2024

    Michael Saylor Has Kept Bitcoin Afloat. What Happens Now as Strategy Prepares to Sell?

    May 28, 2026

    FTSE 100 Sets Up for Fresh Rotation as Investors Look for Post Budget Signals

    November 14, 2025
    Most Popular

    Dow, S&P 500, Nasdaq surge after jobs report, Tesla jumps on Musk-Trump cooldown

    June 6, 2025

    Strive (ASST) Adds 18 Bitcoin, Pushing Treasury To 19,900 BTC

    July 13, 2026

    BTC Price to $150K? Traders say Bitcoin’s Upside Remains Intact

    October 13, 2025
    Editor's Picks

    Bitcoin Millionaires Have Doubled Since Last Year as Markets Heated Up

    August 27, 2024

    Pound steadies near weekly high as US inflation data tests dollar By Investing.com

    April 10, 2026

    Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies

    April 16, 2026
    Facebook X (Twitter) Instagram Pinterest Vimeo
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions
    © 2026 Invest Insider News

    Type above and press Enter to search. Press Esc to cancel.